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Jonathan J. Deeks1, Paulus Kirchhof2,3,4 and Yemisi Takwoingi1Abstract
Background: Atrial fibrillation (AF) is the arrhythmia most commonly diagnosed in clinical practice. It is associated
with significant morbidity and mortality. Prevalence of AF and complications of AF, estimated by hospitalisations,
have increased dramatically in the last decade. Being able to predict AF would allow tailoring of management
strategies and a focus on primary or secondary prevention. Models predicting recurrent AF would have particular
clinical use for the selection of rhythm control therapy. There are existing prognostic models which combine
several predictors or risk factors to generate an individualised estimate of risk of AF. The aim of this systematic
review is to summarise and compare model performance measures and predictive accuracy across different models
and populations at risk of developing incident or recurrent AF.
Methods: Methods tailored to systematic reviews of prognostic models will be used for study identification, risk of
bias assessment and synthesis. Studies will be eligible for inclusion where they report an internally or externally
validated model. The quality of studies reporting a prognostic model will be assessed using the Prediction Study
Risk Of Bias Assessment Tool (PROBAST). Studies will be narratively described and included variables and predictive
accuracy compared across different models and populations. Meta-analysis of model performance measures for
models validated in similar populations will be considered where possible.
Discussion: To the best of our knowledge, this will be the first systematic review to collate evidence from all
studies reporting on validated prognostic models, or on the impact of such models, in any population at risk of
incident or recurrent AF. The review may identify models which are suitable for impact assessment in clinical
practice. Should gaps in the evidence be identified, research recommendations relating to model development,
validation or impact assessment will be made. Findings will be considered in the context of any models already
used in clinical practice, and the extent to which these have been validated.
Systematic review registration: PROSPERO (CRD42018111649).
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Atrial fibrillation (AF) is the most common arrhythmia di-
agnosed in clinical practice, and the worldwide incidence
and prevalence are increasing [1]. AF is predicted to affect
around 18 million people in Europe by 2060, and 6–12
million in the USA by 2050 [1, 2]. Drivers for the increase
in prevalence include an ageing population, better survival
from conditions such as ischaemic heart disease, but also
increasing multimorbidity [3, 4]. AF is associated with in-
creased morbidity, such as stroke or heart failure, and in-
creased mortality, particularly cardiovascular related [3, 4].
Currently available treatments can reduce the mortality
and morbidity associated with AF, particularly via anticoa-
gulation for prevention of strokes [4], but patients with
AF remain at high risk of cardiovascular complications
even on optimal therapy, often manifesting as heart failure
or sudden death [5]. AF also commonly occurs after car-
diac surgery, with patients subsequently at increased risk
of stroke, congestive heart failure, and haemodynamic in-
stability [6]. Post-operative AF rates have been estimated
at up to 60% for cardiothoracic surgery and 5–10% in
non-cardiothoracic surgery [7].
Given the growing burden of AF, there has been a recent
shift in attention to primary and secondary prevention
strategies [8, 9]. It has long been known that approximately
70% of patients experience recurrent AF after, e.g. a cardio-
version [10], while a small population of AF patients does
not show progression of AF, with rare recurrences over de-
cades [11]. Being able to identify those patients who are
most likely to develop recurrent AF, or progress from par-
oxysmal to sustained AF, would be beneficial for tailoring
treatment strategies and implementing targeted preventa-
tive measures. There is a range of risk factors associated
with the development of AF, the best-established ones be-
ing age, hypertension, diabetes mellitus, and heart failure,
as well as environmental factors such as smoking and alco-
hol consumption [12, 13]. Less validated risk factors include
subclinical hyperthyroidism, obesity and sleep apnoea syn-
drome [12]. There may also be a role for biomarkers in
assessing AF risk, including serum biomarkers such as
brain natriuretic peptide (BNP) [14, 15] or fibroblast growth
factor 23 (FGF-23) [14], imaging of atrial function, ECG-
based parameters, and genetic factors [12].
A number of prognostic models, or risk scores,
which attempt to combine several predictors to gen-
erate an individualised estimate of risk in different
populations have been developed for AF prediction.
These include the Cohorts for Ageing and Research
in Genomic Epidemiology (CHARGE)-AF score [16],
the HAVOC score [17], the ATLAS score [18], the
HATCH score [19], and the APPLE score [20].
Scoping searches for existing and ongoing systematic re-
views of prognostic models for AF were carried out in
MEDLINE, Embase, the Cochrane Library, and PROSPERO(October 2018). There were several systematic reviews re-
lating to either the association of individual risk factors with
AF or focussing on a single AF risk prediction model; only
one identified systematic review gave an overview of avail-
able risk scores; this had a focus on recurrence following
catheter ablation [21]. The review had a limited search
strategy and did not include formal quality appraisal of the
identified models. More recent primary studies were identi-
fied since the publication of this review. There is therefore
a need for an up-to-date systematic review, which includes
all relevant populations and uses methodologically robust
methods for study identification, risk of bias assessment,
and synthesis.
Aim
To undertake a systematic review of prognostic models
predicting incident or recurrent AF, with meta-analysis
of model performance measures where possible.
More specifically to
 Identify all studies which report on the
development, validation, or impact of a score for
predicting AF
 Take forward for risk of bias assessment and analysis,
all studies reporting validated models (internal and/
or external validation)
 Summarise and compare model performance
measures and predictive accuracy
 Undertake meta-analysis of model performance
measures where possible
Methods
Study eligibility criteria
Study design
Studies of any design reporting the following types of
prognostic modelling will be eligible for inclusion as
guided by the CHARMS [22] checklist:
 Prediction model development with internal
validation
 Prediction model development with external
validation
 External model validation (with or without model
updating)
Studies reporting impact assessment of a prognostic
model will also be eligible for inclusion.
Studies that have developed a model but not validated
this will not be taken forward for risk of bias assessment
and analysis, but a record of these studies will be kept.
For the purpose of this review, a prognostic model will
be defined as a combination of two or more predictors
within a statistical model, which is used to predict an in-
dividual’s risk of the outcome [23]. Published and
Dretzke et al. Systematic Reviews           (2019) 8:221 Page 3 of 6unpublished studies, as well as studies published in ab-
stract form only, will be eligible for inclusion. Studies
that have looked at the association between a single risk
factor and the development or recurrence of AF will be
excluded, as they are limited in their utility for individual
risk prediction [24].
Patient group
Any population at risk of incident or recurrent AF will
be eligible for inclusion. This will include the general
population; people with cardiovascular disease or other
comorbidities; people who have undergone surgery and
who may be at risk of post-operative AF; and people
who have been treated for AF and are at risk of recur-
rent AF. There will be no restriction on the number or
type of previous treatments. People with paroxysmal,
persistent, or permanent AF will be eligible, and in this
case, models predicting progression from one type of AF
to another will be of interest.
Outcomes
The clinical outcome of interest is incident or recurrent
AF and/or progression from paroxysmal to persistent or
permanent AF. Model performance will be assessed by
calibration measures, i.e. how well the predicted risks
compare to the observed outcome, and discrimination
measures, i.e. how well the model differentiates between
those with and without the outcome [25].
Search strategy
The following bibliographic databases will be searched
(from inception to November 2018) using combinations of
text and index terms relating to the incident or recurrent
AF and models: MEDLINE (Ovid), MEDLINE In-Process
(Ovid), Embase (Ovid), and Cochrane CENTRAL. The
terms relating to the ‘model’ component of the search strat-
egy will be informed by the updates to two existing study
design filters as described by Geersing (2012) [26]. Several
alternate terms will be used, as a prognostic model may also
be described as a prognostic (or prediction) index or rule,
risk (or clinical) prediction model, or predictive model [23].
The term ‘clinical score’ will also be used as well as names
of known scores identified through scoping searches.
Searches will be updated shortly before project completion
to ensure the systematic review is up-to-date at the time of
submission. See Appendix for sample search strategy in
Embase.
There will be no date or language restrictions. Refer-
ence lists of included articles and relevant reviews will
be checked and subject experts consulted. Clinical-
Trials.gov and the WHO International Clinical Trials
Registry Platform will be searched for ongoing studies.
The Conference Proceedings Citation Index will be
searched for conference abstracts.Study selection
All identified studies will be screened independently by
two reviewers (JD, NC) using predefined screening cri-
teria, with disagreements resolved through discussion or
referral to a third reviewer (YT). A sample of records
will be screened by two reviewers to pilot and amend
the screening criteria if necessary, before screening the
remainder. Full texts will be screened where necessary.
Part or full-text translation will be undertaken where ne-
cessary to make selection decisions. The screening
process will be facilitated by the use of reference man-
agement software (EndNote X7) and the selection
process documented using a PRISMA [27] flow diagram.
Data extraction
Data extraction will be undertaken by one reviewer and
checked by a second. A pre-defined and piloted data ex-
traction form (Excel 2016) will be used. Items to data ex-
tract will be guided by the CHARMS [22] checklist and
will include
 Participants (e.g. eligibility and recruitment method,
comorbidities, type and length of treatment for AF,
surgery prior to AF)
 Study design (e.g. randomised controlled trial,
prospective study, sample size, length of follow-up)
 Candidate predictors (e.g. number and type, method
of measurement)
 Outcome measures (e.g. incident or recurrent AF,
how diagnosed)
 Model development (e.g. modelling method, method
for selection of predictors)
 Model performance (discrimination measures, e.g. c-
statistic, and calibration measures, e.g. ratio of
observed and expected events (E/O ratio)
 Model validation (e.g. method for testing model
performance)
Assessment of risk of bias
The quality of studies reporting the development or
validation of a prognostic model will be assessed using
the Prediction Study Risk Of Bias Assessment Tool
(PROBAST) [28]. This assesses criteria within five
domains: participant selection (e.g. were inclusions and
exclusions of participants appropriate); predictors (e.g.
were predictors measured blind to outcome data); out-
comes (e.g. was the same definition used for outcomes
in all patients); sample size and patient flow (e.g. was
there a pre-specified sample size based on estimated
number of outcome events, handling of missing data);
and analysis (e.g. was selection of predictors based on
univariable analysis avoided).
Should impact studies be identified, then additional
quality assessment tools will be used depending on study
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mised controlled trials).
Synthesis
All studies reporting validated prognostic models will be
narratively described, with key findings tabulated (e.g.
predictor variables included in different models, reported
predictive accuracy of models). Models relating to differ-
ent populations will be considered separately. We will
compare model performance across different models,
taking into consideration the quality of the study and
thus the likelihood that model findings are accurate. We
will also compare risk factors included in different
models in order to identify those that are contributing
most to predictive accuracy.
If the same model is validated in several studies, and
the same discrimination or calibration statistics are
reported (e.g. C-statistic, E/O ratio), multivariate random
effects meta-analysis to jointly summarise calibration and
discrimination to obtain average model performance will be
considered. A random effects model is more likely to be
suitable as validation studies typically differ in design and
case-mix, and meta-analysis should allow for the presence
of heterogeneity [25]). The I2 statistic will be used to esti-
mate the proportion of heterogeneity that is due to
between-study variability. Meta-analysis will only be under-
taken for groups of studies including similar populations.
Exploration of heterogeneity through subgroup analyses or
meta-regression is unlikely to be feasible, as a minimum of
10 studies per variable is recommended [25] and scoping
searches indicate lower numbers of studies relating to indi-
vidual models. This also precludes formal exploration of
publication bias using funnel plots.
The body of evidence identified will be considered and
interpreted in the context of the domains described in
the GRADE approach (risk of bias, imprecision, incon-
sistency, indirectness, and publication bias); however, a
formal GRADE score will not be calculated.
Reporting
PRISMA guidelines [27] will be followed for the report-
ing of the systematic review.
Discussion
The increasing burden from AF means that a focus on
prevention is becoming more important, and being able
to identify patients most at risk of incident or recurrent
AF is vital for tailoring management strategies. To the
best of our knowledge, this will be the first systematic
review to collate evidence from all studies reporting on
validated prognostic models, or on the impact of such
models, in any population at risk of incident or recur-
rent AF.We will use recognised systematic review methods for
identifying, appraising, and synthesising the available
evidence on existing prognostic models, which will
strengthen the robustness of any findings. Publication
bias, poor reporting, and extensive heterogeneity are
recognised issues in prognostic research [23–25]. Careful
consideration of heterogeneity before analysis will ensure
that studies are not inappropriately grouped. The poten-
tial impact of publication bias on any findings will be
discussed, and recommendations made for future report-
ing of prognostic models if appropriate.
Should one or more well-validated models with high
predictive accuracy be identified, then this will be useful
for planning future comparative studies on the impact of
using such models in clinical practice. The review will
also identify gaps in the evidence, i.e. where model valid-
ity is poor or where models are lacking for a particular
population. Review findings will therefore inform re-
search recommendations relating to model development,
validation, or impact assessment. Findings will be con-
sidered in the context of any models already used in
clinical practice, and the extent to which these have been
validated.
Appendix
Search strategies Embase and MEDLINE.
1 atrial fibrillation.ti,ab.
2 exp atrial fibrillation/
3 1 OR 2
4 exp recurrent disease/
5 recur$.ti,ab.
6 exp incidence/
7 inciden$.ti,ab.
8 new onset.ti,ab.
9 new$ diagnos$.ti,ab.
10 progress$.ti,ab.
11 prevalen$.ti,ab.
12 exp prevalence/
13 OR/ 4-12
14 prognos$ model$.ti,ab.
15 exp prognosis/ and exp model/
16 predict$ model$.ti,ab.
17 exp prediction/ and exp model/
18 prognos$ index.ti,ab.
19 predict$ index.ti,ab.
20 risk$ predict$.ti,ab.
21 risk$ model$.ti,ab.
22 predict$ rule$.ti,ab.
23 prognos$ rule$.ti,ab.
24 risk score$.ti,ab.
25 clinical score$.ti,ab.
26 prognos$ risk.ti,ab.
27 decision rule$.ti,ab.
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29 model performance.ti,ab.
30 decision model.ti,ab.
31 validation.ti,ab.
32 stratification.ti,ab.
33 ROC curve.ti,ab.
34 exp receiver operating characteristic/
35 discriminat$.ti,ab.
36 c-statistic.ti,ab.
37 "Area under the curve".ti,ab.
38 AUC.ti,ab.
39 Calibration.ti,ab.
40 indices.ti,ab.
41 algorithm.ti,ab.
42 multivaria$.mp.
43 (HATCH adj3 scor$).ti,ab.
44 (ALARMEc adj3 scor$).ti,ab.
45 (BASE-AF2 adj3 scor$).ti,ab.
46 (APPLE adj3 scor$).ti,ab.
47 (CAAP-AF adj3 scor$).ti,ab.
48 (MB-LATER adj3 scor$).ti,ab.
49 (CHARGE-AF adj3 scor$).ti,ab.
50 (HAVOC adj3 scor$).ti,ab.
51 (ATLAS adj3 scor$).ti,ab.
52 (FHS adj3 scor$).ti,ab.
53 (ARIC adj3 scor$).ti,ab.
54 (WHS adj3 scor$).ti,ab.
55 (CHADS2 adj3 scor$).ti,ab.
56 (CHA2DS2-VASC adj3 scor$).ti,ab.
57 (R2CHADS2 adj3 scor$).ti,ab.
58 OR/14-57
59 3 AND 13 AND 58
Abbreviation
AF: Atrial fibrillation
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